Nanoform Finland Oy

Our STARMAP® 2.0 platform leverages cutting-edge sparse-data AI to pick winners among candidate molecules that are predicted to be best amenable to CESS®-powered nanoforming and that exhibit optimal production characteristics.

When existing data alone is not sufficient for generating specific pr...

Why have we developed our bio nanoparticle technology?

The biologics industry is expanding rapidly as the potential of biological therapies grows in recognition. The field is also expected to become more versatile as it grows from antibody-focused production to gene and cell therapies, exosomes,...

We understand that speed is of the essence when working to deliver a life-changing drug to market. Our experienced clinical formulation development team can support formulation development across a vast range of dosage forms – including oral, ophthalmic and transdermal formulations, as well as injectables,...

Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate of 80-90%.

CESS® is a bottom-up method of recrystallization that wo...

NanoImprove the Performance of Your Formulations Small and Large Molecule Formulations Across the Product Life Cycle.NanoImprove Small Molecules
NanoImprove Large Molecules
NanoImprove the Performance of Your BioFormulations With NanoParticles by Design
Nanoforming Success Accelerated by Proprietary AI Technology STARMAP® Drives Predictions of NanoImprovement Success

USFDA 505(b)(2) submissions can be advantageous because they can often lead to faster routes to approval when compared to traditional development pathways while creating new, differentiated products with commercial value. Jamie Unwin, Commercial Insight Officer at Nanoform, sat down with Timothy Pang, Executive Director, Pharma Consulting at Informa Pharma Custom Intelligence to discuss unique performance insights from the last three years for key molecules approved by this pathway, and to reflect on how patient-centric drug development has generated commercial value. Further, they discussed their view on the future direction of the industry with regards to the adoption of 505(b)(2) approaches, and the key technological advances that can empower these. Read on to find out more.

small is green Small empowers your sustainability goals

Cutting-edge nanotechnology is now emerging, with strong clinical evidence, as an alternative to amorphous solid dispersion (ASD), able to not only address bioavailability challenges but also deliver higher drug loads in much more patientfriendly formats with fewer and smaller pills and easier regimens.